#许家印前妻丁玉梅资产冻结范围扩大#【恒大清盘人获批扩大对许家印前妻丁玉梅的资产冻结范围】香 港高等法院26日公布当天作出的一项新裁决，采纳恒大清盘人的主张，扩大对恒大创始人许家印前妻丁 玉梅的资产禁制令，新增其在加拿大、直布罗陀、泽西和新加坡的2.2亿美元资产。（智通财经） ...

近日，湖北宏泰集团召开焕新启航、共创未来——新天风高质量发展大会。湖北省政府有关领导，省有 关部门负责人，湖北宏泰集团党委班子与来自本地22家银行行长、副行长及外地银行、非银金融机构、 在港澳金融机构、评级机构的300余位嘉宾齐聚一堂，共襄新天风高质量发展大计，凝聚金融业高质量 发展合力，为湖北加快建成中部地区崛起的重要战略支点贡献金融力量。 成绩的取得，得益于今年4月启动的天风证券"二次创业"。大投行业务领头突围，自营业务、研究业 务、财富条线齐头并进，串珠成链，带动提升天风证券整体经营效能，形成"主业有保障、辅业有特 色"的业务布局。 2023年2月完成相关股权完成过户，湖北宏泰集团正式开启了天风证券国有控股的序幕。同年3月，宏泰 集团改选天风证券党委，彻底改变了天风证券没有控股股东、没有实际控制人的局面。今年6月，湖北 宏泰集团全额认购了天风证券40亿元定向增发，不仅极大地补充了天风证券的核心净资本，更将宏泰的 持股比例大幅提升，宏泰集团持股比例提升至28.14%（不含一致行动人），进一步夯实了国资实管实 控能力。 服务实体经济、赋能区域发展，数据就是明证。近三年，天风证券累计服务实体经济融资近9300 ...

Core Viewpoint - The beverage industry in China is showing signs of stability and growth, with various companies reporting positive performance across multiple product lines, although there are notable disparities in performance among different categories [1][2][3] Company Performance - China Wangwang reported total revenue of 11.108 billion yuan for the first half of the 2025 fiscal year, a 2.1% increase year-on-year, with dairy and beverage products leading the revenue streams [1] - Wahaha announced a revenue increase of 500 million yuan for 2025, with water products continuing to be a strong growth driver [2] - Genki Forest achieved a 26% year-on-year growth in overall performance for 2025, maintaining double-digit growth for three consecutive years [2] Product Category Insights - Wangwang's beverage segment saw a doubling in sales, with new products contributing nearly 50% to the beverage category's revenue [1] - The performance of functional beverages is on the rise, driven by increasing consumer demand for energy and electrolyte replenishment across various daily scenarios [3][4] - Health-conscious products like sugar-free tea and electrolyte water are gaining traction, particularly among younger demographics [3] Market Trends - The beverage sector is experiencing a divergence in performance, with some companies like Quan Yang Quan reporting revenue and net profit growth, while others focusing on plant-based and dairy beverages face declines [2][4] - Analysts predict that the beverage industry will see a recovery in demand, with expectations of mid-to-high single-digit growth in 2026, influenced by market demand and raw material prices [5]

2025年11月26日，高途集团发布2025财年第三季度财务报告。财报显示，截至2025年9月30日，高途在 第三季度实现收入15.8亿元，同比增长30.7%；现金收入11.9亿元，同比增长11.2%。同时，截至2025年 9月30日，高途于前9个月实现收入44.6亿元，同比增长41.0%，现金收入43.3亿元，同比增长25.4%。 高途宣布，原8000万美元回购计划提前完成，已开启使用新1亿美元回购计划。截至2025年11月25日， 公司在上述两项股票回购计划下累计回购了约2752万美国存托股，金额近6.2亿元。（高途） ...

Core Insights - NIO reported Q3 2025 revenue of 21.79 billion yuan, a year-on-year increase of 16.7% and a quarter-on-quarter increase of 14.7% [1][2] - The net loss for Q3 was 3.48 billion yuan, narrowing by 31.2% year-on-year and 30.3% quarter-on-quarter [1][2] - The company aims to achieve profitability in Q4 2025, with a revenue guidance of 32.76 billion to 34.04 billion yuan, representing a year-on-year growth of 66.3% to 72.8% [3][7] Financial Performance - Q3 automotive sales revenue reached 19.20 billion yuan, up 15.0% year-on-year and 19.0% quarter-on-quarter [4][2] - Gross margin for Q3 was 13.9%, compared to 10.7% in Q3 2024, with automotive gross margin at 14.7% [6][2] - The company’s cash reserves increased to 36.7 billion yuan, up nearly 10 billion yuan from the previous quarter [1] Delivery and Production - NIO achieved a record delivery volume of 87,071 vehicles in Q3, a year-on-year increase of 40.8% and a quarter-on-quarter increase of 20.8% [4][5] - The company expects Q4 deliveries to range between 120,000 and 125,000 vehicles, a year-on-year increase of 65.1% to 72% [4][7] Strategic Outlook - NIO's CEO expressed confidence in achieving profitability in Q4, driven by high-margin models such as the new ES8 and L90 [3][9] - The company plans to launch new models in 2026, aiming for a gross margin of 20% by optimizing costs and focusing on high-end electric vehicles [10][9] - The penetration rate of electric vehicles in the high-end market (over 300,000 yuan) has increased from 12% to 18% in 2023, indicating significant growth potential [9][10]

11月26日，针对近期媒体报道称"特斯拉要求供应商在北美制造环节排除中国零部件"一事，特斯拉全球 副总裁陶琳今日通过社交平台进行了公开回应。陶琳明确表示，特斯拉在全球各地的生产基地对供应商 的选择均采用统一标准，供应商的原产国或地理位置并不构成排除性条件。 陶琳在回应中强调，无论是针对美国、中国还是欧洲市场，特斯拉的供应链策略核心始终围绕质量、总 成本、技术能力成熟度以及长期供货连续性展开。她透露，得益于供应链的深度整合，目前特斯拉上海 超级工厂生产的Model3和Model Y零部件本土化率已超过95%，这直接促成了相关车型在中国市场具有 竞争力的价格体系。(凤凰网科技) ...

Core Viewpoint - Suzhou High-tech (600736) plans to sell 47% equity of Suzhou Medical Device Industry Development Group to Suzhou High-tech State-owned Capital Holding Group for a transaction price of 604.44 million yuan [1] Group 1 - After the transaction, the company's shareholding in the medical device industry company will decrease from 51.37% to 4.37% [1] - The medical device industry company will no longer be included in the consolidated financial statements of the company [1] - The agreement for this transaction has not yet been signed [1]

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for its traditional Chinese medicine "Cough Orange Granules" to conduct clinical trials for new indications [1] Summary by Categories Product Development - The approval allows the company to conduct clinical trials for the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing the lungs [1] - "Cough Orange Granules" is already a product that has been produced and sold by the company, previously classified as a national secondary protected traditional Chinese medicine [1] Regulatory Approval - The clinical trial application was deemed to meet the requirements for drug registration, indicating a positive regulatory response to the company's submission [1] - The approval is based on the latest clinical research and expert consensus, showcasing the company's commitment to expanding the therapeutic applications of its products [1]

Core Viewpoint - Dezheng Health (000813) announced the progress of a lawsuit involving its former controlling shareholder, Meilin Holdings Group, and a related party, Tianbao Jialin International Trade Co., Ltd., which is being sued by Beijing Huaxin Shengrong Information Consulting Co., Ltd. for a contractual dispute [1] Summary by Sections Legal Proceedings - The Beijing Huaxin filed a lawsuit against Tianbao Jialin International Trade Co., Ltd. in the Beijing Third Intermediate People's Court due to a contractual dispute [1] - On November 24, 2025, the company received a ruling from the Beijing High Court that revoked the original ruling of the Beijing Third Intermediate Court and instructed the original court to re-examine the case [1] - The case is still pending trial, and it is currently impossible to assess its impact on the company's current or future profits [1] Company Response - The company emphasizes its commitment to addressing the lawsuit and will actively organize its defense to protect its legal rights and the interests of all shareholders [1]

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors, with no similar drugs approved in the market currently [1] Group 1 - HRS-8364 tablets are a self-developed innovative anti-tumor drug by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - The total R&D investment for the HRS-8364 project has reached approximately 21.65 million yuan [1] Group 2 - The approval for clinical trials is a significant step, but the drug must still undergo clinical trials and regulatory reviews before it can be manufactured and marketed [1] - The drug development process is lengthy and involves uncertainties, which necessitates cautious decision-making by investors [1]